ArticleRadiology and oncology2013

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.

Alessandro Tuzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.